

# CITATION REPORT

List of articles citing

Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence

DOI: 10.1097/qco.00000000000000216

Current Opinion in Infectious Diseases, 2015, 28, 576-82.

**Source:** <https://exaly.com/paper-pdf/60724822/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
73	Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166451	3.7	27
72	Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 721-31	5.5	8
71	Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. <i>Biomaterials</i> , <b>2016</b> , 108, 1-12	15.6	12
70	Building the evidence base to eliminate hepatitis B and C as public health threats. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1314-1316	25.5	3
69	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1385-1398	25.5	159
68	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , <b>2016</b> , 65, S33-S45	45.4	111
67	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. <i>Hepatology</i> , <b>2016</b> , 64, 1911-1921	11.2	44
66	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 733-741	3.4	46
65	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , <b>2017</b> , 14, 110-121	5.9	37
64	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. <i>Current Epidemiology Reports</i> , <b>2017</b> , 4, 174-185	2.9	31
63	Belgian experience with direct acting antivirals in people who inject drugs. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 177, 214-220	4.9	26
62	Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 169-176	5.5	4
61	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 325-336	18.8	153
60	HCV reinfection incidence among individuals treated for recent infection. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 359-370	3.4	48
59	Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 171, 132-139	4.9	2
58	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 230-238	5.5	23
57	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services For Persons Who Inject Drugs [United States, 2015]2016. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 1945-1948	8.7	5

56	Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, e25013	5.4	37
55	Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling. <i>Handbook of Statistics</i> , <b>2017</b> , 37, 93-119	0.6	
54	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 811-817	3.4	19
53	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21 Suppl 2, e25051	5.4	27
52	Hepatitis C: from discovery to cure. <i>ISBT Science Series</i> , <b>2018</b> , 13, 244-251	1.1	
51	2017 European guideline for the screening, prevention and initial management of hepatitis B and C infections in sexual health settings. <i>International Journal of STD and AIDS</i> , <b>2018</b> , 29, 949-967	1.4	5
50	Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 460-463	11.6	39
49	Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. <i>Journal of Virus Eradication</i> , <b>2018</b> , 4, 118-122	2.8	10
48	Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206356	3.7	7
47	Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. <i>MDM Policy and Practice</i> , <b>2018</b> , 3, 2381468318776634	1.5	20
46	Hepatitis C infection and psychiatric burden in two imprisoned cohorts: Young offenders and opioid-maintained prisoners. <i>Health Policy</i> , <b>2018</b> , 122, 1392-1402	3.2	1
45	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2018</b> , 15, 412-424	24.2	45
44	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , <b>2018</b> , 32, 371-393	6.5	18
43	Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C. <i>Current HIV/AIDS Reports</i> , <b>2018</b> , 15, 245-254	5.9	53
42	A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons. <i>Harm Reduction Journal</i> , <b>2018</b> , 15, 39	4.6	5
41	Bighting a losing battle—prisoners' perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures. <i>Drugs: Education, Prevention and Policy</i> , <b>2019</b> , 26, 502-507	1.2	2
40	High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 181-188	5.5	12
39	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , <b>2019</b> , 9, e029538	3	16

38	Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 1236-1242	1.9	10
37	Cure and Control: What Will It Take to Eliminate HCV?. <i>Topics in Medicinal Chemistry</i> , <b>2019</b> , 447-490	0.4	1
36	Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 1255-1263	25.5	17
35	Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 100, 45-51	4.2	28
34	Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 189-194	5.5	6
33	Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 177-180	5.5	4
32	Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 169-176	5.5	21
31	Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. <i>Harm Reduction Journal</i> , <b>2019</b> , 16, 32	4.6	10
30	Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz125	1	2
29	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. <i>Epidemics</i> , <b>2019</b> , 27, 86-95	5.1	9
28	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 363-371	11.6	11
27	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1502-1510	11.6	20
26	Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2020</b> , 32, 921-929	2.2	2
25	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , <b>2020</b> , 40, 51-59	7.9	2
24	Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. <i>Medicine (United States)</i> , <b>2020</b> , 99, e22005	1.8	1
23	How to think with models and targets: Hepatitis C elimination as a numbering performance. <i>International Journal of Drug Policy</i> , <b>2021</b> , 88, 102694	5.5	10
22	Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 303-311	13.4	5
21	Management of Hepatitis C Viral Infection in People Who Inject Drugs. <b>2021</b> , 191-211		

20	Viral hepatitis C pandemic: Challenges and threats to its elimination. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 694-698	3.4	1
19	Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245896	3.7	4
18	Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. <i>Global Public Health</i> , <b>2021</b> , 1-13	3.5	2
17	Excitable models: Projections, targets, and the making of futures without disease. <i>Sociology of Health and Illness</i> , <b>2021</b> , 43, 859-880	3	6
16	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , <b>2021</b> , 116, 2893-2907	4.6	9
15	Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	0
14	Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1744-1750	3.4	1
13	Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland. <i>International Journal of Drug Policy</i> , <b>2021</b> , 96, 103434	5.5	0
12	Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they?. <b>2020</b> , 106-111		1
11	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016. <i>Morbidity and Mortality Weekly Report</i> , <b>2017</b> , 66, 465-469	31.7	56
10	Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. <i>Statistical Communications in Infectious Diseases</i> , <b>2021</b> , 13,	0.7	
9	Autophagy in Viral Infection and Pathogenesis. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 766147	4.7	3
8	Insights into Hepatitis C Transmission in Young Persons who Inject Drugs: Results From a Dynamic Modeling Approach Informed by State-Level Public Health Surveillance Data.		
7	HIV, Hepatitis C, TB, Harm Reduction, and Persons Deprived of Liberty: What Standards Does International Human Rights Law Establish?. <i>Health and Human Rights</i> , <b>2016</b> , 18, 171-182	1.1	8
6	Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. <i>Journal of Virus Eradication</i> , <b>2018</b> , 4, 118-122	2.8	5
5	Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	
4	Hepatitis C microelimination among people living with HIV in Taiwan. <i>Emerging Microbes and Infections</i> , 1-29	18.9	0
3	Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. <b>2022</b> , 2, e0000841		

- 2 Pilot Outreach Program in Remedise The Promising Step toward HCV Elimination among People Who Inject Drugs. **2023**, 20, 501 ○
- 1 Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya. **2023**, 113, 103959 ○